F
FuturedMe
FuturedMe Inc.- A pioneer in the science of using novel protein degradation CANDDYTM Platform towards “No Patients without Medicine”-
About FuturedMe
FuturedMe Inc. is at the forefront of developing innovative drug design technologies, specifically focusing on novel protein degradation. The company operates in the biotechnology sector and targets patients who currently lack effective treatments for their conditions. Utilizing the proprietary CANDDYTM Platform, FuturedMe transforms undruggable targets into druggable ones, offering new hope for patients with diseases that have no specific medicines available. The business model revolves around research and development, with revenue generated through partnerships, grants, and potentially future drug sales. The company serves a niche market of patients with rare or difficult-to-treat diseases, leveraging cutting-edge science to meet unmet medical needs.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Tokyo, Japan
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
JAFCO
UntroD Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about FuturedMe on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See FuturedMe on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.